

### Oral Solid Dosage Pharmaceutical Formulation-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/O14F61E351AMEN.html

Date: February 2018 Pages: 155 Price: US\$ 3,480.00 (Single User License) ID: O14F61E351AMEN

### Abstracts

#### **Report Summary**

Oral Solid Dosage Pharmaceutical Formulation-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oral Solid Dosage Pharmaceutical Formulation industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Oral Solid Dosage Pharmaceutical Formulation 2013-2017, and development forecast 2018-2023

Main market players of Oral Solid Dosage Pharmaceutical Formulation in EMEA, with company and product introduction, position in the Oral Solid Dosage Pharmaceutical Formulation market

Market status and development trend of Oral Solid Dosage Pharmaceutical Formulation by types and applications

Cost and profit status of Oral Solid Dosage Pharmaceutical Formulation, and marketing status

Market growth drivers and challenges

The report segments the EMEA Oral Solid Dosage Pharmaceutical Formulation market as:

EMEA Oral Solid Dosage Pharmaceutical Formulation Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):



Europe Middle East Africa

EMEA Oral Solid Dosage Pharmaceutical Formulation Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

By Form Capsules Powders Tablets By Drug Release Mechanism Immediate Release Extended Release

EMEA Oral Solid Dosage Pharmaceutical Formulation Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals Clinics Other

EMEA Oral Solid Dosage Pharmaceutical Formulation Market: Players Segment Analysis (Company and Product introduction, Oral Solid Dosage Pharmaceutical Formulation Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca Plc. Bristol-Myers Squibb Company Eli Lilly and Company Gilead Sciences Merck & Co. Inc. Novartis AG Pfizer Inc. AbbVie Inc. Boehringer Ingelheim GmbH Hoffman-La-Roche Ltd.

Oral Solid Dosage Pharmaceutical Formulation-EMEA Market Status and Trend Report 2013-2023



Johnson & Johnson Biogen Inc. Bayer AG Teva Pharmaceticals Amgen Inc. Takeda Pharmaceutical Company Ltd. Otsuka Pharmaceutical Co., Ltd. Shire Plc. Celgene Corporation Astellas Pharma Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



### Contents

# CHAPTER 1 OVERVIEW OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 1.1 Definition of Oral Solid Dosage Pharmaceutical Formulation in This Report
- 1.2 Commercial Types of Oral Solid Dosage Pharmaceutical Formulation
- 1.2.1 By Form
- 1.2.2 Capsules
- 1.2.3 Powders
- 1.2.4 Tablets
- 1.2.5 By Drug Release Mechanism
- 1.2.6 Immediate Release
- 1.2.7 Extended Release
- 1.3 Downstream Application of Oral Solid Dosage Pharmaceutical Formulation
  - 1.3.1 Hospitals
  - 1.3.2 Clinics
- 1.3.3 Other
- 1.4 Development History of Oral Solid Dosage Pharmaceutical Formulation

1.5 Market Status and Trend of Oral Solid Dosage Pharmaceutical Formulation 2013-2023

1.5.1 EMEA Oral Solid Dosage Pharmaceutical Formulation Market Status and Trend 2013-2023

1.5.2 Regional Oral Solid Dosage Pharmaceutical Formulation Market Status and Trend 2013-2023

#### CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Oral Solid Dosage Pharmaceutical Formulation in EMEA 2013-2017

2.2 Consumption Market of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Regions

2.2.1 Consumption Volume of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Regions

2.2.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Regions

2.3 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Regions

2.3.1 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Europe 2013-2017



2.3.2 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Middle East 2013-2017

2.3.3 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Africa 2013-2017

2.4 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation in EMEA 2018-2023

2.4.1 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation in EMEA 2018-2023

2.4.2 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation by Regions 2018-2023

#### CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Types

3.1.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Types 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Types

# CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Downstream Industry

4.2 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Major Countries

4.2.1 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Europe

4.2.2 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Middle East

4.2.3 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Africa

4.3 Market Forecast of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Downstream Industry



#### CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

5.1 EMEA Economy Situation and Trend Overview

5.2 Oral Solid Dosage Pharmaceutical Formulation Downstream Industry Situation and Trend Overview

#### CHAPTER 6 ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Major Players

6.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in EMEA by Major Players

6.3 Basic Information of Oral Solid Dosage Pharmaceutical Formulation by Major Players

6.3.1 Headquarters Location and Established Time of Oral Solid Dosage Pharmaceutical Formulation Major Players

6.3.2 Employees and Revenue Level of Oral Solid Dosage Pharmaceutical

Formulation Major Players

6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

#### CHAPTER 7 ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AstraZeneca Plc.

- 7.1.1 Company profile
- 7.1.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.1.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of AstraZeneca Plc.

7.2 Bristol-Myers Squibb Company

- 7.2.1 Company profile
- 7.2.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.2.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company



7.3 Eli Lilly and Company

7.3.1 Company profile

7.3.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.3.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

7.4 Gilead Sciences

7.4.1 Company profile

7.4.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.4.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Gilead Sciences

7.5 Merck & Co. Inc.

7.5.1 Company profile

7.5.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.5.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Merck & Co. Inc.

7.6 Novartis AG

7.6.1 Company profile

7.6.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.6.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Novartis AG

7.7 Pfizer Inc.

7.7.1 Company profile

7.7.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.7.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Pfizer Inc.

7.8 AbbVie Inc.

7.8.1 Company profile

7.8.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.8.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of AbbVie Inc.

7.9 Boehringer Ingelheim GmbH

7.9.1 Company profile

7.9.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.9.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

7.10 Hoffman-La-Roche Ltd.

7.10.1 Company profile

7.10.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.10.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and



Gross Margin of Hoffman-La-Roche Ltd.

- 7.11 Johnson & Johnson
- 7.11.1 Company profile

7.11.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.11.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and

Gross Margin of Johnson & Johnson

7.12 Biogen Inc.

7.12.1 Company profile

7.12.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.12.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Biogen Inc.

7.13 Bayer AG

7.13.1 Company profile

7.13.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.13.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and

Gross Margin of Bayer AG

7.14 Teva Pharmaceticals

7.14.1 Company profile

7.14.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.14.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Teva Pharmaceticals

7.15 Amgen Inc.

7.15.1 Company profile

7.15.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.15.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Amgen Inc.

7.16 Takeda Pharmaceutical Company Ltd.

7.17 Otsuka Pharmaceutical Co., Ltd.

7.18 Shire Plc.

7.19 Celgene Corporation

7.20 Astellas Pharma Inc.

# CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 8.1 Industry Chain of Oral Solid Dosage Pharmaceutical Formulation
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis



#### CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 9.1 Cost Structure Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.2 Raw Materials Cost Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.3 Labor Cost Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.4 Manufacturing Expenses Analysis of Oral Solid Dosage Pharmaceutical Formulation

#### CHAPTER 10 MARKETING STATUS ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
- 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

#### **CHAPTER 11 REPORT CONCLUSION**

#### CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



#### I would like to order

Product name: Oral Solid Dosage Pharmaceutical Formulation-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/O14F61E351AMEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

#### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/O14F61E351AMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Oral Solid Dosage Pharmaceutical Formulation-EMEA Market Status and Trend Report 2013-2023